Values First Advisors, Inc. Sage Therapeutics, Inc. Transaction History
Values First Advisors, Inc.
- $177 Million
- Q4 2024
A detailed history of Values First Advisors, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 21,249 shares of SAGE stock, worth $149,592. This represents 0.06% of its overall portfolio holdings.
Number of Shares
21,249
Previous 27,947
23.97%
Holding current value
$149,592
Previous $201,000
42.79%
% of portfolio
0.06%
Previous 0.11%
Shares
10 transactions
Others Institutions Holding SAGE
# of Institutions
194Shares Held
45MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$36.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$34.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$32.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$31.4 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$21.1 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $418M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...